![]() ![]() Clinical Data for Nonhospitalized Patients With COVID-19 There is insufficient evidence for the Panel to recommend either for or against the use of vitamin C for the treatment of COVID-19 in nonhospitalized patients.īecause patients who are not critically ill with COVID-19 are less likely to experience oxidative stress or severe inflammation, the role of vitamin C in this setting is unknown. ![]() Recommendation for Nonhospitalized Patients With COVID-19 It is an antioxidant and free radical scavenger that has anti-inflammatory properties, influences cellular immunity and vascular integrity, serves as a cofactor in endogenous catecholamine generation, and has been studied in many disease states, 1,2 including COVID-19. Vitamin C (ascorbic acid) is a water-soluble vitamin that has been considered for potential beneficial effects in patients with varying degrees of illness severity. Results from adequately powered, well-designed, and well-conducted clinical trials are needed to provide further guidance on the role of vitamin C in the prevention and treatment of COVID-19. ![]() The studies summarized in this section have had the greatest impact on the COVID-19 Treatment Guidelines Panel’s (the Panel) recommendations. ![]() In addition, the study designs had different doses or formulations of vitamin C and different outcome measures, and the study populations included patients with varying concomitant medications and COVID-19 disease severity. However, most of these studies had significant limitations, such as a small sample size or a lack of randomization or blinding. Since the most recent revision of this section, the results from several cohort studies, clinical trials, and meta-analyses on the use of vitamin C in patients with COVID-19 have been published in peer-reviewed journals or have been made available as manuscripts before peer review. ![]()
0 Comments
Leave a Reply. |